Home > > > Radiopharmaceutical for Nuclear Medicine Market to Reach USD 9.1 Billion by 2034 | CAGR 4.7%

Radiopharmaceutical for Nuclear Medicine Market to Reach USD 9.1 Billion by 2034 | CAGR 4.7%

Author : shivani ghodake | Published On : 02 Oct 2026

According to a report by IntelMarketResearch, global Radiopharmaceutical for Nuclear Medicine market was valued at USD 5.8 billion in 2025 and is projected to reach USD 6.3 billion in 2026 before growing to USD 9.1 billion by 2034, registering a CAGR of 4.7% during the forecast period. Market growth is being driven by increasing use of radiopharmaceuticals for diagnosis and treatment, rising adoption of targeted radionuclide therapies, advances in radioisotope production, and expanding nuclear medicine infrastructure.

Explore the full report: https://www.intelmarketresearch.com/radiopharmaceutical-for-nuclear-medicine-market-37921

Why Is Demand Increasing

 

  • Expansion of Therapeutic Applications: Radiopharmaceutical use is moving beyond traditional diagnostic imaging toward targeted therapies, particularly for oncology applications involving therapeutic radioisotopes.
  • Growth of Targeted Radionuclide Therapy: Lutetium-177 and Actinium-225-based approaches are supporting the development of targeted treatments for cancers and other specialized indications.
  • Advances in Radioisotope Production: Investment in cyclotron-based, reactor-based, and other isotope-production technologies is supporting supply diversification and the development of new radiopharmaceutical products.

 

Radiopharmaceutical Watch: Theranostics

Theranostic approaches are becoming an important area of innovation by combining diagnostic imaging with targeted treatment. Radiopharmaceutical pairs can help identify patients with specific molecular targets and subsequently deliver therapeutic radioisotopes to those targets, supporting more personalized nuclear medicine pathways.

Explore the full report: https://www.intelmarketresearch.com/radiopharmaceutical-for-nuclear-medicine-market-37921

Segmentation Highlights

 

  • By Type: Carbon-14, Technetium-99m, Iodine-131, Iodine-125, and Others.
  • By Application: Nuclear Medicine Diagnosis, Nuclear Medicine Treatment, and Others.
  • By Regional Market: North America, Europe, Asia-Pacific, South America, and Middle East & Africa, with country-level analysis included in the report.

 

Regional Outlook

 

  • North America: The dominant regional market, supported by advanced PET and SPECT infrastructure, strong R&D activity, regulatory frameworks, reimbursement systems, and growing adoption of targeted radionuclide therapies.
  • Asia-Pacific: The fastest-growing region, driven by healthcare infrastructure expansion, increasing disease burden, government investment, growing radiopharmaceutical manufacturing capacity, and rising nuclear medicine adoption across China, Japan, South Korea, India, and Australia.

 

Download the free sample report: https://www.intelmarketresearch.com/download-free-sample/37921/radiopharmaceutical-for-nuclear-medicine-market

Why This Market Matters

Radiopharmaceuticals are specialized radioactive compounds used for both diagnostic imaging and therapeutic applications in nuclear medicine. Their increasing role in oncology, cardiovascular care, and other clinical areas is creating opportunities for radioisotope producers, pharmaceutical companies, healthcare providers, and technology developers. The market is also being shaped by supply-chain requirements, specialized production infrastructure, regulatory standards, and advances in precision medicine.

Competitive Landscape

 

  • NRG: A major radioisotope producer supporting the global supply chain for nuclear medicine applications.
  • NTP Radioisotopes: Provides medical radioisotopes and related nuclear medicine supply capabilities.
  • ANSTO: Supports radioisotope production and nuclear medicine supply from Australia.
  • Curium Pharma: Develops and supplies diagnostic and therapeutic radiopharmaceutical products.
  • Lantheus Holdings: Focuses on diagnostic imaging and radiopharmaceutical solutions, including products used in nuclear medicine.

 

View the full report: https://www.intelmarketresearch.com/radiopharmaceutical-for-nuclear-medicine-market-37921

FAQ

What is the Radiopharmaceutical for Nuclear Medicine market size? The global market was valued at USD 5.8 billion in 2025 and is projected to reach USD 9.1 billion by 2034 at a CAGR of 4.7%.

What are the major applications? Major applications include nuclear medicine diagnosis and nuclear medicine treatment.

Which region dominates the market? North America is the dominant regional market, while Asia-Pacific is identified as the fastest-growing region.

What Does the Full Report Cover?

The full Radiopharmaceutical for Nuclear Medicine market report covers market size and forecasts, type and application segmentation, regional analysis, country-level markets, competitive landscape, key companies, industry trends, market drivers, restraints, opportunities, radioisotope production, therapeutic applications, diagnostic applications, supply-chain developments, and emerging theranostic technologies. The report also evaluates the evolving role of targeted radionuclide therapies and innovations in radiopharmaceutical manufacturing.

View the complete report: https://www.intelmarketresearch.com/radiopharmaceutical-for-nuclear-medicine-market-37921

Download the free sample: https://www.intelmarketresearch.com/download-free-sample/37921/radiopharmaceutical-for-nuclear-medicine-market

Related Reports

 

 

About IntelMarketResearch

IntelMarketResearch provides market intelligence, industry analysis, competitive assessments, and strategic research across global industries. Its reports deliver market sizing, forecasts, segmentation, regional analysis, company profiles, and insights into emerging technologies and business trends.

Contact Details

IntelMarketResearch Website: https://www.intelmarketresearch.com Email: [email protected] Phone: +91 916 916 4321 Linkedin: Follow us